LordsMed Joins Hands With Hindustan Antibiotics To Distribute Rapid Antigen Kits
LordsMed, the healthcare division of Lord’s Mark Industries, has entered into a distribution partnership with Hindustan Antibiotics Limited (HAL), a public-sector drug manufacturer. The healthcare company will manufacture rapid antigen test kits at its ICMR-approved GMP and ISO-certified facility
LordsMed, the healthcare division of Lord’s Mark Industries, has entered into a distribution partnership with Hindustan Antibiotics Limited (HAL), a public-sector drug manufacturer. The healthcare company will manufacture rapid antigen test kits at its ICMR-approved GMP and ISO-certified facility at Vasai, near Mumbai, Maharashtra, and distribute those kits in government healthcare centres across India at an affordable rate—10 per cent less than the average market rates, the company said in a statement on Wednesday.
The broadening of the distribution network is part of LordsMed's goal of facilitating early-stage healthcare intervention and generating Rs 75 crore in revenue in six months, the statement said.
LordsMed has recently received ICMR approval to manufacture rapid antigen test kits at its Vasai facility for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, typhoid, COVID, chikungunya, ovulation, and pregnancy.
The company said it has developed a robust R&D team comprised of experienced microbiologists and doctors and has emerged as the only IVD kit manufacturing company in India, working to roll out saliva-based diagnostic solutions for a range of diseases. The company has successfully carried out trials of its saliva-based diagnostics kits for diabetes and liver diseases.
Commenting on the partnership with HAL, Sachidanand Upadhyay, Founder, Lord’s Mark Industries, said, “The distribution partnership with HAL will help us reach out to all parts of the country cities including metros, Tier -1, 2 and 3 cities and rural areas with our affordable and advanced rapid antigen test kits. The collaboration is a part of our mission to build a robust early-stage healthcare intervention framework and boost the responsiveness of the healthcare ecosystem."
The company stated its future plans to set up a manufacturing unit in Gujarat by 2023 and another facility in Lucknow, Uttar Pradesh, by 2024 to further boost its manufacturing capabilities and serve the growing market demand. The company also has plans to expand its exports to all countries in Africa and Europe.